CA3098514A1 - Mesenchymal stromal cell exosomes and uses thereof - Google Patents

Mesenchymal stromal cell exosomes and uses thereof Download PDF

Info

Publication number
CA3098514A1
CA3098514A1 CA3098514A CA3098514A CA3098514A1 CA 3098514 A1 CA3098514 A1 CA 3098514A1 CA 3098514 A CA3098514 A CA 3098514A CA 3098514 A CA3098514 A CA 3098514A CA 3098514 A1 CA3098514 A1 CA 3098514A1
Authority
CA
Canada
Prior art keywords
subject
msc
thymic
administered
exosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3098514A
Other languages
English (en)
French (fr)
Inventor
Stella KOUREMBANAS
S. Alexander Mitsialis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA3098514A1 publication Critical patent/CA3098514A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3098514A 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof Pending CA3098514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664696P 2018-04-30 2018-04-30
US62/664,696 2018-04-30
PCT/US2019/029275 WO2019217091A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
CA3098514A1 true CA3098514A1 (en) 2019-11-14

Family

ID=68466806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3098514A Pending CA3098514A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Country Status (6)

Country Link
US (1) US12521418B2 (https=)
EP (1) EP3810271A4 (https=)
JP (2) JP7538044B2 (https=)
CN (1) CN112334190B (https=)
CA (1) CA3098514A1 (https=)
WO (1) WO2019217091A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN111281889A (zh) * 2020-04-16 2020-06-16 博生众康(厦门)医药生物技术股份有限公司 人脐带间充质干细胞外泌体的用途
KR20230004709A (ko) * 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN117363568B (zh) * 2023-12-04 2024-04-09 山东大学 一种脂肪间充质干细胞外泌体及其制备方法与应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
EP1937801A1 (en) 2005-09-02 2008-07-02 Agency for Science, Technology and Research Method of deriving mesenchymal stem cells
US20090274665A1 (en) 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
PT2578081E (pt) 2006-10-11 2016-06-17 Massachusetts Inst Technology Composições, métodos e dispositivos para o tratamento de doenças hepáticas
EP1944361A1 (en) 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
AU2009203638C1 (en) 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
SG177467A1 (en) 2009-07-23 2012-02-28 Agency Science Tech & Res Pre-natal mesenchymal stem cells
WO2011053257A2 (en) 2009-11-02 2011-05-05 Agency For Science, Technology And Research (A*Star) Methods of monitoring cellular states
KR101189655B1 (ko) 2010-06-30 2012-10-11 성균관대학교산학협력단 줄기세포 배양액을 포함하는 폐질환 치료용 조성물
CN101890050B (zh) 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
WO2012020308A2 (en) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
US9901600B2 (en) 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
JP2014519340A (ja) 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
EP2833893B1 (en) 2012-04-03 2018-08-29 Reneuron Limited Stem cell microparticles
KR101399056B1 (ko) 2012-04-16 2014-05-27 연세대학교 산학협력단 줄기세포-유래 미세소포체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약제학적 조성물
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
US20150125950A1 (en) 2012-05-18 2015-05-07 Agency For Science, Technology And Research (A*Sta (A*Star) Umbilical cord mesenchymal stem cell exosomes
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
JP2015524849A (ja) 2012-08-15 2015-08-27 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 神経変性疾患に対するエキソソームに基づく治療法
CN103767985A (zh) 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
US20160002597A1 (en) 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
JP2016528151A (ja) 2013-08-07 2016-09-15 ピーアイ セラミック ゲーエムベーハー 鉛含有量が低減された圧電セラミック材料
WO2015038075A1 (en) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
WO2016043654A1 (en) 2014-09-15 2016-03-24 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US20180273906A1 (en) * 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
AU2017220148A1 (en) * 2016-02-18 2018-07-19 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
CN105769916B (zh) 2016-04-29 2019-07-23 南京大学 间充质干细胞来源外泌体在制备治疗子痫前期药物或者制剂中的应用
CA3027970A1 (en) 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency
KR101973284B1 (ko) * 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물
US11760975B2 (en) 2017-03-31 2023-09-19 Wisconsin Alumi Research Foundation Generation of therapeutic cells using extracellular components of target organs
CN111212653A (zh) 2017-08-15 2020-05-29 儿童医学中心公司 经纯化间充质干细胞外排体及其用途
US11499730B2 (en) 2018-02-12 2022-11-15 Wisconsin Alumni Research Foundation LPS priming of stromal cells to generate LPS-specific exosome educated macrophages
CA3099042A1 (en) 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
EP3846782A4 (en) 2018-09-05 2022-07-13 Children's Medical Center Corporation Use of mesenchymal stromal cell exosomes in antenatal therapy

Also Published As

Publication number Publication date
WO2019217091A1 (en) 2019-11-14
EP3810271A1 (en) 2021-04-28
CN112334190B (zh) 2024-09-20
CN112334190A (zh) 2021-02-05
US20210137989A1 (en) 2021-05-13
JP2021523106A (ja) 2021-09-02
US12521418B2 (en) 2026-01-13
EP3810271A4 (en) 2022-01-26
JP2024138218A (ja) 2024-10-08
JP7538044B2 (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
US12521418B2 (en) Mesenchymal stromal cell exosomes and uses thereof
Chaubey et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6
US20200306319A1 (en) Methods for treating radiation or chemical injury
Tokalov et al. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats
EP2001998B1 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
JP7563976B2 (ja) 歯髄由来細胞の製造方法
US20250170183A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
US9926561B2 (en) Composition for regenerating normal tissue from fibrotic tissue
US20210213056A1 (en) Mesenchymal stromal cell exosome-treated monocytes and uses thereof
KR20200128501A (ko) 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
Abedi et al. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process
EP4017512B1 (en) Compositions for monocyte and macrophage polarization and methods of use
JP2022517342A (ja) 幹細胞機能を向上させるための薬剤及び方法
WO2021153719A1 (ja) 歯髄由来細胞を含む医薬組成物
US12090166B2 (en) Pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, containing LPAR2 inhibitor
Class et al. Patent application title: MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF
Park et al. Co-transplantation of human mesenchymal stem cells promotes human CD34+ cells engraftment in a dose-dependent fashion in NOD/SCID mice
JP2023543149A (ja) 幹細胞機能を向上させるための組成物及び方法
RU2795621C2 (ru) Способ получения клеток из зубной пульпы
KR101813079B1 (ko) 에키노크롬 a를 유효성분으로 함유하는 심근세포 분화유도용 조성물
WO2026096838A1 (en) Treatment of organ dysfunction using a combination of mesenchymal stem cells and exosomes
Osman Kuersetin Ile ZenginleŞTirilmiŞ Kordon KaynaklI Mezenkimal KÖK HÜCre EksozomlarININ, LPS IndÜKlÜ HMC3 Mikroglia NÖRoinflamasyon Modelinde, Antienflamatuar Etkisinin Incelenmesi
JP2018074983A (ja) 未分化細胞が除去された分化誘導細胞集団の製造方法
EP1951214A2 (en) Modulation of osteoclast differentiation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724